Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 8 | 2024 | 691 | 2.960 |
Why?
|
| Wearable Electronic Devices | 6 | 2024 | 65 | 2.410 |
Why?
|
| Cannabis | 3 | 2023 | 47 | 2.280 |
Why?
|
| Telemedicine | 5 | 2024 | 336 | 2.110 |
Why?
|
| Craving | 3 | 2024 | 35 | 1.740 |
Why?
|
| Cannabinoids | 3 | 2023 | 35 | 1.720 |
Why?
|
| Drug Overdose | 6 | 2023 | 120 | 1.550 |
Why?
|
| Opioid-Related Disorders | 9 | 2024 | 465 | 1.530 |
Why?
|
| Substance Abuse Detection | 3 | 2016 | 39 | 1.490 |
Why?
|
| Fat Emulsions, Intravenous | 4 | 2015 | 36 | 1.430 |
Why?
|
| Biosensing Techniques | 5 | 2017 | 114 | 1.190 |
Why?
|
| Stress, Psychological | 2 | 2024 | 443 | 1.180 |
Why?
|
| Mobile Applications | 5 | 2024 | 130 | 1.180 |
Why?
|
| Cocaine | 4 | 2015 | 86 | 1.110 |
Why?
|
| Monitoring, Ambulatory | 3 | 2016 | 56 | 1.080 |
Why?
|
| Analgesics, Opioid | 9 | 2024 | 495 | 1.020 |
Why?
|
| Machine Learning | 3 | 2022 | 135 | 0.870 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2019 | 35 | 0.820 |
Why?
|
| Hallucinogens | 1 | 2022 | 14 | 0.790 |
Why?
|
| Smartphone | 4 | 2024 | 62 | 0.790 |
Why?
|
| Toxicology | 2 | 2024 | 34 | 0.770 |
Why?
|
| Circulating MicroRNA | 1 | 2019 | 6 | 0.680 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 41 | 0.660 |
Why?
|
| Acetaminophen | 1 | 2019 | 52 | 0.650 |
Why?
|
| Emergency Service, Hospital | 9 | 2024 | 1022 | 0.570 |
Why?
|
| Systems Integration | 1 | 2017 | 27 | 0.560 |
Why?
|
| Glass | 1 | 2017 | 21 | 0.560 |
Why?
|
| Transducers | 1 | 2017 | 27 | 0.560 |
Why?
|
| Transcriptome | 1 | 2019 | 329 | 0.540 |
Why?
|
| Humans | 33 | 2024 | 59426 | 0.530 |
Why?
|
| Secondary Prevention | 1 | 2016 | 153 | 0.500 |
Why?
|
| Hemodynamics | 2 | 2013 | 235 | 0.500 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 75 | 0.490 |
Why?
|
| Social Media | 1 | 2017 | 112 | 0.480 |
Why?
|
| Pilot Projects | 7 | 2021 | 922 | 0.450 |
Why?
|
| Male | 20 | 2024 | 27550 | 0.440 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2013 | 15 | 0.440 |
Why?
|
| Research Design | 1 | 2017 | 567 | 0.440 |
Why?
|
| Epinephrine | 1 | 2013 | 42 | 0.440 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 64 | 0.420 |
Why?
|
| Naloxone | 3 | 2023 | 54 | 0.400 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 2067 | 0.390 |
Why?
|
| Adult | 13 | 2024 | 15761 | 0.390 |
Why?
|
| Skin | 1 | 2015 | 356 | 0.390 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 819 | 0.380 |
Why?
|
| Galvanic Skin Response | 3 | 2016 | 21 | 0.380 |
Why?
|
| Biomedical Research | 3 | 2024 | 250 | 0.360 |
Why?
|
| Heart Rate | 3 | 2020 | 306 | 0.350 |
Why?
|
| Narcotic Antagonists | 3 | 2021 | 114 | 0.340 |
Why?
|
| Financing, Government | 2 | 2020 | 33 | 0.340 |
Why?
|
| Buprenorphine | 2 | 2023 | 186 | 0.330 |
Why?
|
| Pain Management | 2 | 2024 | 145 | 0.330 |
Why?
|
| Young Adult | 4 | 2024 | 4319 | 0.300 |
Why?
|
| Female | 15 | 2024 | 30886 | 0.300 |
Why?
|
| Middle Aged | 8 | 2024 | 16250 | 0.290 |
Why?
|
| Acute Pain | 2 | 2017 | 20 | 0.280 |
Why?
|
| Emergency Medicine | 2 | 2020 | 185 | 0.280 |
Why?
|
| Oxycodone | 2 | 2017 | 32 | 0.280 |
Why?
|
| Child | 3 | 2022 | 4305 | 0.280 |
Why?
|
| Faculty, Medical | 2 | 2019 | 203 | 0.270 |
Why?
|
| Logistic Models | 2 | 2021 | 1252 | 0.270 |
Why?
|
| Skin Temperature | 2 | 2016 | 18 | 0.260 |
Why?
|
| Fractures, Bone | 2 | 2017 | 139 | 0.260 |
Why?
|
| Wrist | 2 | 2016 | 32 | 0.250 |
Why?
|
| Self Report | 2 | 2020 | 366 | 0.250 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 569 | 0.250 |
Why?
|
| Adolescent | 3 | 2021 | 5917 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 796 | 0.230 |
Why?
|
| Sentinel Surveillance | 1 | 2024 | 20 | 0.230 |
Why?
|
| Dronabinol | 1 | 2023 | 29 | 0.220 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 119 | 0.220 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 1548 | 0.210 |
Why?
|
| Random Allocation | 2 | 2013 | 198 | 0.210 |
Why?
|
| Rats | 4 | 2013 | 1913 | 0.210 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 135 | 0.210 |
Why?
|
| Psychometrics | 1 | 2024 | 356 | 0.200 |
Why?
|
| Research Support as Topic | 2 | 2019 | 44 | 0.200 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2020 | 113 | 0.200 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 4 | 0.200 |
Why?
|
| Mentors | 2 | 2020 | 117 | 0.200 |
Why?
|
| Cholinergic Antagonists | 2 | 2019 | 30 | 0.190 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 117 | 0.190 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 13 | 0.190 |
Why?
|
| Seizures | 1 | 2022 | 118 | 0.190 |
Why?
|
| Aged | 5 | 2024 | 13339 | 0.190 |
Why?
|
| Decision Making | 1 | 2024 | 391 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2013 | 521 | 0.180 |
Why?
|
| Drug Users | 1 | 2021 | 28 | 0.180 |
Why?
|
| Eating | 1 | 2021 | 139 | 0.180 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 21 | 0.170 |
Why?
|
| Wireless Technology | 1 | 2020 | 18 | 0.170 |
Why?
|
| Time Factors | 2 | 2019 | 3577 | 0.160 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 48 | 0.160 |
Why?
|
| Research Personnel | 1 | 2020 | 86 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 71 | 0.160 |
Why?
|
| United States | 5 | 2024 | 7513 | 0.160 |
Why?
|
| Mindfulness | 1 | 2020 | 64 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 354 | 0.160 |
Why?
|
| Efficiency | 1 | 2018 | 41 | 0.150 |
Why?
|
| Medication Adherence | 2 | 2017 | 254 | 0.150 |
Why?
|
| Naltrexone | 1 | 2019 | 75 | 0.150 |
Why?
|
| Writing | 1 | 2018 | 43 | 0.150 |
Why?
|
| Medical Informatics Applications | 1 | 2017 | 15 | 0.150 |
Why?
|
| Incidence | 1 | 2021 | 1237 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 229 | 0.140 |
Why?
|
| Music Therapy | 1 | 2017 | 16 | 0.140 |
Why?
|
| Telemetry | 1 | 2017 | 20 | 0.140 |
Why?
|
| Alcoholism | 1 | 2020 | 307 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 903 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 56 | 0.140 |
Why?
|
| Prognosis | 1 | 2021 | 1572 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1027 | 0.140 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 98 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 702 | 0.130 |
Why?
|
| Forecasting | 1 | 2017 | 221 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 59 | 0.130 |
Why?
|
| Equipment Design | 1 | 2017 | 317 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 804 | 0.130 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2016 | 75 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 122 | 0.130 |
Why?
|
| Motion | 1 | 2015 | 55 | 0.130 |
Why?
|
| Locomotion | 1 | 2016 | 110 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2020 | 3096 | 0.120 |
Why?
|
| Body Temperature | 1 | 2015 | 43 | 0.120 |
Why?
|
| Age Factors | 1 | 2019 | 1516 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 151 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 448 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2019 | 1306 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6001 | 0.120 |
Why?
|
| Chronic Pain | 1 | 2017 | 142 | 0.120 |
Why?
|
| Biomarkers | 1 | 2019 | 1197 | 0.120 |
Why?
|
| Algorithms | 1 | 2020 | 991 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2019 | 846 | 0.120 |
Why?
|
| Infant | 1 | 2019 | 1522 | 0.120 |
Why?
|
| Animals | 5 | 2015 | 19643 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2019 | 1838 | 0.110 |
Why?
|
| Anticholinergic Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
|
| beta-Alanine | 1 | 2013 | 9 | 0.110 |
Why?
|
| Atropine | 1 | 2013 | 13 | 0.110 |
Why?
|
| Sodium Chloride | 1 | 2013 | 57 | 0.110 |
Why?
|
| Pain | 1 | 2017 | 405 | 0.110 |
Why?
|
| Antithrombins | 1 | 2013 | 16 | 0.110 |
Why?
|
| Muscarinic Antagonists | 1 | 2013 | 26 | 0.110 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2013 | 28 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2013 | 39 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2013 | 59 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2015 | 527 | 0.100 |
Why?
|
| Cyclohexylamines | 1 | 2012 | 5 | 0.100 |
Why?
|
| Mitragyna | 1 | 2012 | 5 | 0.100 |
Why?
|
| Salvia | 1 | 2012 | 3 | 0.100 |
Why?
|
| Cyclohexanones | 1 | 2012 | 5 | 0.100 |
Why?
|
| Alkaloids | 1 | 2012 | 11 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2013 | 268 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2019 | 5170 | 0.100 |
Why?
|
| Kinetics | 1 | 2013 | 731 | 0.100 |
Why?
|
| Piperazines | 1 | 2012 | 80 | 0.100 |
Why?
|
| Survival Rate | 1 | 2013 | 790 | 0.090 |
Why?
|
| Psychotropic Drugs | 1 | 2012 | 83 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2013 | 524 | 0.090 |
Why?
|
| Risk Factors | 1 | 2019 | 5010 | 0.080 |
Why?
|
| Massachusetts | 1 | 2015 | 2095 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5098 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2594 | 0.060 |
Why?
|
| Fever | 1 | 2024 | 63 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2024 | 104 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2023 | 26 | 0.050 |
Why?
|
| Focus Groups | 1 | 2024 | 293 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 330 | 0.050 |
Why?
|
| Community Health Services | 1 | 2023 | 128 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 33 | 0.050 |
Why?
|
| Hospitals | 1 | 2024 | 376 | 0.050 |
Why?
|
| Opiate Substitution Treatment | 1 | 2023 | 192 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 617 | 0.040 |
Why?
|
| Phenotype | 1 | 2024 | 1150 | 0.040 |
Why?
|
| Harm Reduction | 1 | 2020 | 24 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2019 | 22 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 117 | 0.040 |
Why?
|
| Capsules | 1 | 2017 | 31 | 0.040 |
Why?
|
| Pain Perception | 1 | 2017 | 7 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 315 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 485 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2017 | 27 | 0.040 |
Why?
|
| Radio Waves | 1 | 2017 | 18 | 0.030 |
Why?
|
| Drug Approval | 1 | 2017 | 27 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 961 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 108 | 0.030 |
Why?
|
| Affect | 1 | 2017 | 121 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 95 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 541 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 330 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 360 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 330 | 0.030 |
Why?
|
| Bleeding Time | 1 | 2013 | 5 | 0.030 |
Why?
|
| Women's Health | 1 | 2017 | 390 | 0.030 |
Why?
|
| Dabigatran | 1 | 2013 | 23 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 169 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 344 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 715 | 0.020 |
Why?
|